Acute myeloid leukaemia (C92.0, C92.3-C92.5, C93.0, C94.0, C94.2, C94.4, C94.5)
The following material has been sourced from the Australian Institute of Health and Welfare
|Incidence - Males||Incidence - Females||Incidence - Persons||Mortality - Males||Mortality - Females||Mortality - Persons|
|2011 incidence/2012 mortality(b)|
|Risk to age 75||1 in 328||1 in 478||1 in 390||1 in 444||1 in 608||1 in 514|
|Risk to age 85||1 in 174||1 in 264||1 in 212||1 in 174||1 in 272||1 in 216|
|Estimated number for 2014, 2015 and 2016(c)|
Figure B2(a): Incidence and mortality ASRs(b,c) of acute myeloid leukaemia, 1982-2016
Figure B2(b): Incidence (2011) and mortality (2012) rates of acute myeloid leukaemia, by age group
- Based on IARC (2014) and WCRF & AICR (2007) (see Chapter 2).
- The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the ACT (see Appendix F, Cancer in Australia: an overview 2014). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population.
- The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 2002–2012 mortality data (see Appendix G, Cancer in Australia: an overview 2014). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to nearest 5. The estimates for males and females may not add to estimates for persons due to rounding.
Sources: AIHW ACD 2011; AIHW NMD.
Table B2(b): Survival and prevalence of acute myeloid leukaemia
|Prevalence as at the end of 2009(a)|
|Relative survival in 2007-2011(b)|
|1-year relative survival at diagnosis (%)||40.1||42.0||40.9|
|95% confidence interval||37.9-42.2||39.5-44.4||39.3-42.5|
|5-year relative survival at diagnosis (%)||23.4||26.1||24.5|
|95% confidence interval||21.6-25.2||24.0-28.2||23.2-25.9|
|5-year conditional relative survival for those already survived 1 year after diagnosis (%)||55.7||60.1||57.7|
|95% confidence interval||50.8-60.6||55.2-65.0||54.2-61.2|
|5-year conditional relative survival for those already survived 5 years after diagnosis (%)||87.6||91.1||89.3|
|95% confidence interval||84.2-91.0||88.3-93.9||87.1-91.5|
Figure B2(c): Relative survival at diagnosis and 5-year conditional survival from acute myeloid leukaemia, Australia, 2007–2011
- Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases.
- Relative survival was calculated with the period method, using the period 2007-2011 (Brenner & Gefeller 1996). Note that this period does not contain incidence data for 2010-2011 for NSW or the ACT (see Appendix F, Cancer in Australia: an overview 2014).
Source: AIHW ACD 2011.